Long-Term study sheds light on rare bone and hormone disorder
NCT ID NCT00209235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 600 people with Albright hereditary osteodystrophy, a rare genetic condition affecting bones and hormones. Researchers are looking at how growth hormone treatment affects height and weight in those with a related hormone problem, and also studying thinking and behavior. The goal is to learn more about the condition and find better ways to manage it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALBRIGHT HEREDITARY OSTEODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Connecticut Children's Medical Center
Hartford, Connecticut, 06103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Why are people with this rare bone disorder prone to diabetes?
- Single-Patient trial aims to tackle obesity in rare bone disorder
- Old asthma drug shows promise for rare genetic disorder
- Could a common asthma drug help treat a rare genetic disorder?
- Old asthma drug could help kids with rare bone and hormone disorder